Rapid Micro Biosystems, Inc. Stock Price, News & Analysis

Rapid Micro Biosystems (NASDAQ: RPID) has appointed Dr. Dafni Bika to its Board of Directors. Dr. Bika brings over 25 years of leadership experience in pharmaceutical development and manufacturing science. She currently serves as Senior Vice President and Global Head of Pharmaceutical Technology and Development at AstraZeneca plc, leading global teams in advancing synthetic molecules into approved medicines. Previously, she held senior executive roles at Bristol-Myers Squibb and served as Director of Global Pharmaceutical Commercialization at Merck. Dr. Bika holds a Ph.D. in Materials Science and Engineering from the University of Pennsylvania and will contribute to establishing the Growth Direct platform as the industry standard for automating pharmaceutical QC testing.

Rapid Micro Biosystems (NASDAQ: RPID) reported strong Q1 2025 financial results with total revenue of $7.2 million, representing a 28% growth year-over-year. The company achieved record quarterly service revenue of $3.1 million, up 64% from Q1 2024. Product revenue increased 10% to $4.1 million, while recurring revenue grew 6% to $4.0 million.

Notable achievements include placing three new Growth Direct® systems and completing nine customer system validations. Gross margin improved significantly to positive 6% from negative 27% in Q1 2024. Operating expenses decreased 5% to $12.1 million, and net loss improved to $11.3 million ($0.26 per share) from $13.3 million ($0.31 per share) year-over-year.

The company announced a global Distribution and Collaboration Agreement with MilliporeSigma and reaffirmed its 2025 revenue guidance of at least $32.0 million, targeting 21-25 system placements.

Rapid Micro Biosystems (Nasdaq: RPID), a life sciences technology company specializing in automation solutions for healthcare product manufacturing, has scheduled its first quarter 2025 financial results announcement for May 9, 2025, before market opening.

The company will host a webcast conference call at 8:30 a.m. ET on the same day, with management discussing the results. The webcast will be available on the company's website and archived for future reference.

Rapid Micro Biosystems (NASDAQ: RPID) has announced new equity grants as inducement awards to three new employees. The grants include:

- 50,000 restricted stock units (RSUs) granted on March 3, 2025

- 250,000 non-qualified stock options and 174,000 RSUs granted on March 10, 2025

The stock options have an exercise price of $2.27 per share. The vesting schedule includes:

• Options: 25% vest after one year, followed by 1/48th monthly
• RSUs: One-third vests annually over three years

All grants were made under the Company's Inducement Plan and approved in accordance with Nasdaq Listing Rule 5635(c)(4), specifically for new employees who were not previously employed by the company.

Rapid Micro Biosystems (RPID) reported strong Q4 2024 results with record revenue of $8.2 million, up 30% year-over-year. The company achieved full-year 2024 revenue of $28.1 million, representing 25% growth compared to 2023.

Q4 highlights include six Growth Direct system placements, 27% increase in product revenue to $5.2 million, and 35% growth in service revenue to $3.0 million. The company demonstrated significant margin improvement, reaching a record Q4 gross margin of 12%, up 15 percentage points from Q4 2023.

For full-year 2024, RPID placed 21 Growth Direct systems and completed 16 system validations, reaching 162 cumulative systems placed globally. The company projects 2025 revenue of at least $32.0 million with 21-25 planned system placements. Additionally, RPID announced a global Distribution and Collaboration Agreement with MilliporeSigma.

Rapid Micro Biosystems (NASDAQ: RPID) has entered into a five-year global distribution and collaboration agreement with MilliporeSigma, the Life Science business of Merck KGaA. The partnership grants MilliporeSigma global co-exclusive rights to sell Growth Direct systems and related consumables across pharmaceutical, medical device, personal care, cosmetics, and food and beverage sectors worldwide.

The agreement includes minimum purchase commitments for Growth Direct systems in the first two years. Rapid Micro will maintain its existing sales channels and continue handling system installation, validation, and service. The collaboration aims to explore cost savings through MilliporeSigma's manufacturing capabilities, with potential for joint technology development and service enhancements.

Rapid Micro Biosystems (Nasdaq: RPID), a life sciences technology company specializing in automation solutions for healthcare product manufacturing, has announced its participation in two upcoming investor conferences.

The company will deliver a presentation at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 11:10 a.m. ET in Boston, Massachusetts. Additionally, RPID will participate in a Q&A session at the KeyBanc Capital Markets Healthcare Forum, a virtual event scheduled for March 19, 2025, at 11:15 a.m. ET.

Both events will be accessible via live webcasts on the company's investor relations website at investors.rapidmicrobio.com, with recordings available for replay after the events.

Rapid Micro Biosystems (Nasdaq: RPID) has scheduled the release of its fourth quarter and full year 2024 financial results before market opening on February 28, 2025. The company, which specializes in providing automation solutions for healthcare product manufacturing, will accompany the results announcement with a webcast conference call hosted by the management team at 8:00 a.m. ET on the same day. The webcast will be available on the company's website and will remain accessible for replay after the event.

Rapid Micro Biosystems (NASDAQ: RPID) reported preliminary unaudited results for Q4 and full year 2024. The company expects record Q4 2024 revenue of $8.2 million, up 30% year-over-year, with recurring revenue of $4.2 million, up 27%. Full-year 2024 revenue is anticipated at $28.1 million, representing 25% growth, with recurring revenue of $15.5 million, up 14%.

The company placed six new Growth Direct systems and validated four customer systems in Q4, bringing total placements to over 160 systems and over 135 validated systems globally. Additionally, RPID announced a collaboration with Lonza, integrating Growth Direct with Lonza's MODA-EM module to create the first fully automated end-to-end environmental monitoring QC solution, which Lonza is deploying across its global cell and gene therapy manufacturing network.